{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:06:11Z","timestamp":1760853971993},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2709-x","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T21:20:53Z","timestamp":1504560053000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique"],"prefix":"10.1186","volume":"17","author":[{"given":"Andrea","family":"De Luca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zita Jorge","family":"Sidumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Zanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noorjehan Abdul","family":"Magid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Luhanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Liotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Mancinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Marazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Palombi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Ceffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"key":"2709_CR1","unstructured":"World Health Organization. HIV drug resistance report 2017. Geneva: World Health Organization. 2017. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"2709_CR2","volume-title":"Guidelines on the public health response to pre-treatment HIV drug resistance","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L, Aves T, Borhan S, Leenus A, Jordan MJ, Parkin N, et al. Systematic reviews and meta-analyses used to inform the World health Organization Guidelines on the public health response to pre-treatment HIV drug resistance. 2017. [Publication pending]. Web Annex 2. In: Guidelines on the public health response to pre-treatment HIV drug resistance. Geneva: World health Organization; 2017. available at \nhttp:\/\/who.int\/hiv\/pub\/guidelines\/hivdr-guidelines-2017\/\n\n."},{"key":"2709_CR3","volume-title":"Second edition","author":"WHO","year":"2016","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and prevent HIV infection: recommendations for a public health approach. In: Second edition; 2016. \nhttp:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf?ua=1\n\n."},{"key":"2709_CR4","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/jac\/dkr171","volume":"66","author":"MC Prosperi","year":"2011","unstructured":"Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, et al. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 2011;66:1886\u201396.","journal-title":"J Antimicrob Chemother"},{"key":"2709_CR5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/jac\/dkv473","volume":"71","author":"QD Pham","year":"2016","unstructured":"Pham QD, Wilson DP, Nguyen TV, Do NT, Truong LX, Nguyen LT, et al. Projecting the epidemiological effect, cost-effectiveness and transmission of HIV drug resistance in Vietnam associated with viral load monitoring strategies. J Antimicrob Chemother. 2016;71:1367\u201379.","journal-title":"J Antimicrob Chemother"},{"key":"2709_CR6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/QAI.0b013e31824276e9","volume":"59","author":"A Luca De","year":"2012","unstructured":"De Luca A, Marazzi MC, Mancinelli S, Ceffa S, Altan AM, Buonomo E, et al. Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2012;59:236\u201344.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2709_CR7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/cid\/cir729","volume":"53","author":"HE Rawizza","year":"2011","unstructured":"Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankal\u00e8 JL, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011;53:1283\u201390.","journal-title":"Clin Infect Dis"},{"key":"2709_CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/QAI.0b013e318227fc34","volume":"58","author":"KC Sigaloff","year":"2011","unstructured":"Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011;58:23\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2709_CR9","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1093\/jac\/dkv143","volume":"70","author":"M Ruperez","year":"2015","unstructured":"Ruperez M, Pou C, Macaluve S, Cedeno S, Luis L, Rodriguez J, et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. J Antimicrob Chemother. 2015;70:2639\u201347.","journal-title":"J Antimicrob Chemother"},{"key":"2709_CR10","unstructured":"DREAM Community of Sant\u2019Egidio. The goal of a dream. Achieving millenium development goals. \nhttp:\/\/dream.santegidio.org\/wp-content\/uploads\/2015\/01\/DREAM_MDG_def.pdf\n\n."},{"key":"2709_CR11","unstructured":"UNAIDS.HIV and AIDS estimates. 2015. \nhttp:\/\/www.unaids.org\/en\/regionscountries\/countries\/mozambique\/\n\n."},{"key":"2709_CR12","doi-asserted-by":"publisher","first-page":"e0130580","DOI":"10.1371\/journal.pone.0130580","volume":"10","author":"DCA Bila","year":"2015","unstructured":"Bila DCA, Boullosa LT, Vubli AS, Mabunda NJ, Abreu CM, Ismael N, et al. Trends in prevalence of HIV-1 drug resistance in a public clinic in Maputo, Mozambique. PLoS One. 2015;10:e0130580. \ndoi:10.1371\/journal.pone.0130580\n\n.","journal-title":"PLoS One"},{"key":"2709_CR13","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/infdis\/jit109","volume":"207","author":"A Luca De","year":"2013","unstructured":"De Luca A, Hamers RL, Shapiro JM. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries. J Infect Dis. 2013;207:S63\u20139.","journal-title":"J Infect Dis"},{"key":"2709_CR14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/aid.2011.0136","volume":"28","author":"KC Sigaloff","year":"2012","unstructured":"Sigaloff KC, Ramatsebe T, Viana R, de Wilt TF, Wallis CL, Stevens WS. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retrovirus. 2012;28:171\u20135.","journal-title":"AIDS Res Hum Retrovirus"},{"key":"2709_CR15","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1097\/INF.0b013e3181e47609","volume":"29","author":"RK Gupta","year":"2010","unstructured":"Gupta RK, Ford D, Mulenga V, Walker AS, Kabamba D, Kalumbi M, et al. Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. Pediatr Infect Dis J. 2010;29:e57\u201362.","journal-title":"Pediatr Infect Dis J"},{"key":"2709_CR16","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/jac\/dkw583","volume":"72","author":"RL Goodall","year":"2017","unstructured":"Goodall RL, Dunn DT, Nkurunziza P, Mugarura L, Pattery T, Munderi P, et al. Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa. J Antimicrob Chemother. 2017;72:1450\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"2709_CR17","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","volume":"71","author":"TS Boender","year":"2016","unstructured":"Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, et al. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J Antimicrob Chemother. 2016;71:2918\u201327.","journal-title":"J Antimicrob Chemother"},{"key":"2709_CR18","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1089\/aid.2016.0010","volume":"32","author":"E Guichet","year":"2016","unstructured":"Guichet E, Aghokeng A, Serrano L, Bado G, Toure-Kane C, Eymard-Duvernay S, et al. Short Communication: High viral load and multidrug resistance due to late switch to second-line regimens could be a major obstacle to reach the 90-90-90 UNAIDS objectives in sub-Saharan Africa. AIDS Res Hum Retrovir. 2016;32:1159\u201362.","journal-title":"AIDS Res Hum Retrovir"},{"key":"2709_CR19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/cid\/cis501","volume":"55","author":"JH Brehm","year":"2012","unstructured":"Brehm JH, Koontz DL, Wallis CL, Shutt KA, Sanne I, Wood R, et al. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis. 2012;55:737\u201345.","journal-title":"Clin Infect Dis"},{"key":"2709_CR20","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/infdis\/jis261","volume":"11","author":"KC Sigaloff","year":"2012","unstructured":"Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa. J Infect Dis. 2012;11:1739\u201344.","journal-title":"J Infect Dis"},{"key":"2709_CR21","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","volume":"4","author":"NI Paton","year":"2017","unstructured":"Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, et al. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Lancet HIV. 2017;4:e341\u20138.","journal-title":"Lancet HIV"},{"key":"2709_CR22","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(14)00061-7","volume":"2","author":"MA Boyd","year":"2015","unstructured":"Boyd MA, Moore CL, Molina JM, Wood R, Madero JS, Wolff M, et al. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysys. Lancet HIV. 2015;2:e42\u201351.","journal-title":"Lancet HIV"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T21:21:05Z","timestamp":1504560065000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2709-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2709"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2709-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,5]]},"article-number":"605"}}